Complement‐mediated cell killing of breast, lung and ovarian tumour cells by combined trastuzumab and pertuzumab was previously shown to be efficient only when all three CD46, CD55 and CD59 mCRPs were suppressed using the siRNA gene silencing technology (Mamidi et al., 2013). The gene discussed is CD46; the disease is ovarian neoplasm.